According to a study published by Insure Insights, the sepsis diagnostic market is estimated to grow at a CAGR of 9.8% during the forecast period. Sepsis is a life-threatening condition caused by the uncontrolled response of the body to an infection. Normally, the body releases chemicals into the bloodstream to fight against antigens. Sepsis occurs when these chemicals are released in an uncontrolled manner and damage multiple organ systems. If sepsis progresses to septic shock, blood pressure drops dramatically, leading to death. Sepsis generally occurs in the geriatric population, people suffering from chronic diseases such as diabetes, kidney or lung conditions, pregnant women, and infants.
Top Driver: Rising Prevalence of Sepsis and Hospital Acquired Infections
The major factor driving the global sepsis diagnostic market is the rising prevalence of sepsis around the world. According to the World Health Organization (WHO), 2018 statistics, sepsis affected around 30 million people in the world, and more than 3 million newborns and 1.2 million children suffer from sepsis globally each year. In addition, the data provided by the Centers for Disease Control and Prevention (CDC), more than 1.5 million people in the U.S. suffer from sepsis annually, and around 2,50,000 Americans die each year due to sepsis. This has encouraged the government to carry out a diagnosis for sepsis at a huge scale every year.
Other factors, such as the growing geriatric population, increasing health awareness, and rising prevalence of chronic disorders, are the other factors fueling the growth of the global sepsis diagnostic market. Besides, a high incidence of hospital-acquired infection is the prominent factor anticipated to stimulate the sepsis diagnostic market during the forecast period.
Laboratory Testing Anticipated to Witness Growth During the Forecast Period
Based on the diagnostic type, the sepsis diagnostic market has been segmented into laboratory testing and PoC testing. The laboratory testing segment accounts for the largest market share and is anticipated to continue its dominance during the forecast period owing to the rising number of blood culture tests conducted in the laboratories. The rising number of laboratories and healthcare expenditure to develop advanced instruments in developed as well as in developing countries is are estimated to foster the laboratory testing segment.
By product, the market is segmented into instruments, assay kits, blood culture media, and others. Blood culture media holds the largest market share owing to its cost-effectiveness and is considered as the gold standard.
Based on the technology, the market is segmented into immunoassay, microbiology, molecular diagnostic, and others. The molecular diagnostic is anticipated to witness growth in the near future, owing to its high accuracy and sensitivity.
Based on the pathogen, the market has been segmented into fungal sepsis, bacterial sepsis, and others. A high prevalence of bacteria is attributing to the growth of the bacterial sepsis segment.
Rising Prevalence of Sepsis to Benefit North America Market
North America holds the largest market share in the global sepsis diagnostic market and is estimated to show a similar trend during the forecast period. One of the primary factors responsible is the rising incidence of sepsis in countries such as the United States and Canada, thereby encouraging the government for rapid diagnosis. According to the CDC statistics in 2018, sepsis affects more than a million Americans every year and leads to 15% to 30% deaths in the United States. The rising prevalence of sepsis is attributed to a few factors, such as the growing geriatric population, rising incidence of incurable infections, and the majority of the population who have undergone an organ transplant.
Players to Focus on Strategic Acquisition and Product Development
Some of the prominent players operating in the global sepsis diagnosis market are bioMérieux SA, Beckman Coulter, Inc., Becton, Dickinson and Company, Sysmex Corporation, F. Hoffmann-La Roche AG, and Thermo Fisher Scientific, Inc.
Beckman Coulter: In May 2020, Beckman Coulter announced an expanded partnership with BARDA as part of their rapidly expanding COVID-19 medical countermeasure portfolio. The partnership was awarded to Beckman Coulter, in collaboration with Dascena, Inc., for additional advanced research and development toward optimization of a machine-learning-based sepsis diagnostic and prediction algorithm to include assessing its use with coronavirus (COVID-19) patients.
Sysmex Corporation: In September 2019, Sysmex Corporation introduced the HISCL Presepsin Assay Kit for Sepsis Testing. The assay kit can be used with its Automated Immunoassay System HISCL-5000/2000i/800 for immunochemistry testing (HISCL-Series). This reagent is used for measuring levels of presepsin, a major test parameter for bacterial sepsis.
Scope of the Report
By Diagnostic method
Key Reasons to Purchase this Report
Table of Content
Please fill out the form to receive sample pages of the report